Back to Search
Start Over
Comprehensive evaluation of Impella RP ® in right ventricular failure.
- Source :
-
Future cardiology [Future Cardiol] 2022 Apr; Vol. 18 (4), pp. 285-298. Date of Electronic Publication: 2022 Feb 21. - Publication Year :
- 2022
-
Abstract
- Right ventricular failure has a high morbidity and mortality in patients suffering from advanced heart failure, pulmonary hypertension, acute myocardial infarction after cardiac surgery and in left ventricular assist device patients. The Impella RP <superscript>®</superscript> catheter is a mechanical circulatory device, positioned from a venous femoral percutaneous access and passing through the tricuspid and pulmonary valves, reaches the pulmonary artery. Impella RP (Abiomed Inc., MA, USA) acts as a direct right ventricle bypass and it provides a flow up to 4.4 liters per minute, unloading the right ventricle. The main contraindications are: thrombi in the vena cava, right atrium and ventricle and pulmonary artery; mechanical tricuspid or pulmonary prostheses. In this review, the principles of operations, clinical applications and results of Impella RP are summarized and evaluated.
Details
- Language :
- English
- ISSN :
- 1744-8298
- Volume :
- 18
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Future cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 35187952
- Full Text :
- https://doi.org/10.2217/fca-2021-0075